Currently, we have 6 ongoing programmes that are either in full development or ready to start clinical trials in humans.

As of April 2020, several patent applications describing our innovative formulations, drug delivery methods and target indications have been filed to the European Patent Office for review. Consequently, we cannot publicly disclose these activities until we receive the necessary patent protection for our programmes. However, Cannovex is open for partnerships and is always willing to provide additional information to interested parties (info@www.cannovex.com)